Robert Magnon, MD
Dermatology · Sequin, TXNPI 1013993096
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 63.8% of it on its own, with 13 other manufacturers making up the rest. That places this record below the midpoint for dermatology clinicians in TX, where the typical reported total is $4,085.
Across 115 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$229
- Sanofi$132
- Sun Pharmaceutical Industries Inc.$80
- Pfizer$67
- Lilly USA, LLC$51
- plus $234 from 8 others
What the payments were for
- Food & beverage$2,17599%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 72 | $1,396 |
| Novartis | 11 | $229 |
| Sanofi | 8 | $132 |
| Sun Pharmaceutical Industries Inc. | 4 | $80 |
| Pfizer | 4 | $67 |
| Lilly USA, LLC | 2 | $51 |
| Galderma Laboratories, L.p. | 2 | $46 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $38 |
| LEO Pharma Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Dermavant Sciences, Inc. | 2 | $29 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Organon | 1 | $15 |
| Verrica Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,189 in reported general payments places this provider in the 35th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 14 | $95,361 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $79,793 |
| Cyclosporine | 16 | $5,017 |
| Clobetasol Propionate | 83 | $4,925 |
| Doxycycline Hyclate | 177 | $4,687 |
| Fluocinonide | 128 | $4,147 |
| Mupirocin | 641 | $4,107 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 220 | $4,105 |
| Triamcinolone Acetonide | 454 | $3,957 |
| Minocycline Hcl | 78 | $1,826 |
| Metronidazole | 27 | $1,788 |
| Fluorouracil | 29 | $1,369 |
| Dexamethasone | 196 | $959 |
| Ketoconazole | 36 | $573 |
| Doxycycline Monohydrate | 12 | $481 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Sequin
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- Daniel CarrascoAustin$1.1M
- Dale SchaeferAustin$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.